Myelofibrosis

Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which prevents the normal production of blood cells. The condition is a primary subtype of myeloproliferative neoplasms (MPNs) and, in some cases, starts as another MPN. Risk factors for primary MF are unclear, although a history of polycythemia vera (PV) or essential thrombocythemia (ET) are risk factors for development of secondary MF. The disease is stratified as low, intermediate, or high risk using various International Prognostic Scoring System scales, and the prognosis depends on individual risk factors including age, comorbidities, and treatment response.

Advertisement
Advertisement
Prithviraj Bose, MDMeeting News | December 30, 2024
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Prithviraj Bose, MDMeeting News | December 30, 2024
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
Key takeaways from the top ASH abstracts in the myelofbrosis space.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
A roundtale discussion starts with a conversation about the myelofibrosis treatment landscape.
John Mascarenhas, MDMeeting News | December 26, 2024
Discussing current clinical trials iand unmet needs in myelofibrosis.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
The PROMise trial aims to examine the safety and preliminary efficacy of OPN-2853 with ruxolitinib for MF treatment.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
Odyssey is an ongoing, open-label, phase 2 study that will assess the benefit of adding luspatercept to momelotinib.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
At ASH 2024, updated results of the RESTORE trial were presented.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
These real-world findings highlight momelotinib as an effective and practical treatment for managing MF in everyday practice
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
BOREAS is the first global phase 3 study to demonstrate clinical efficacy of a single-agent treatment for r/r myelofibrosis.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
John Masarenhas discussed the development of the human telomerase inhibitor imetelstat for the treatment of myelofibrosis.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
Improvements in the frequency of transfusions and of anemia symptoms are interventional priorities for myelofibrosis.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
A phase 2 trial showed selinexor was well tolerated, and further studies are investigating its efficacy in other MF settings.
Blood Cancers Today Staff WritersMeeting News | December 18, 2024
Ruxolitinib is the standard of care for patients with MF; however, it does not address the significant anemia burden.
Blood Cancers Today Staff WritersMeeting News | December 18, 2024
A retrospective, real-world analysis shows momelotinib reduces anemia in patients with myelofibrosis.
Blood Cancers Today Staff WritersMeeting News | December 13, 2024
HOPE-PMF will recruit 150 participants with prefibrotic PMF or PMF at low or intermediate-1 risk.
Blood Cancers Today Staff WritersMeeting News | December 13, 2024
Study findings indicate that allo-HSCT may offer a potentially curative treatment for high-risk BP-MF patients.
Blood Cancers Today Staff WritersMeeting News | December 13, 2024
The safety was improved and the symptom burden of MF was reduced and remarked that the high burden of inflammation.
Blood Cancers Today Staff WritersMeeting News | December 12, 2024
Benefits were observed of flonoltinib maleate in myelofibrosis were observed regardless of prior JAK inhibitor exposure.
Blood Cancers Today Staff WritersMeeting News | December 11, 2024
Harinder Gill, MBBS, MD et al deems bomedemstat/ruxolitinib safe and tolerable for second-line MDS treatment.
Blood Cancers Today Staff WritersMeeting News | December 11, 2024
Patients in a phase 1 study saw remarkable symptom improvements with INCB057643 and tolerated treatment well.
Blood Cancers Today Staff WritersMeeting News | December 11, 2024
Hispanic ethnicity and prior transplants mismatched unrelated donors were prognostic of worse outcomes in older MF patients.
Blood Cancers Today Staff WritersMeeting News | December 11, 2024
A trial in progress, phase 3 IMpactMF trial, investigates the encouraging efficacy/safety of imetelstat in MF.
Melissa BadamoMyelofibrosis | November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Melissa BadamoMyelofibrosis | November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.
Melissa BadamoMyelofibrosis | November 4, 2024
Selinexor plus ruxolitinib was well tolerated, reduced symptom burden, and led to spleen volume reduction.
Melissa BadamoMyelofibrosis | November 4, 2024
One year of pacritinib treatment stabilized or improved thrombocytopenia and anemia in patients with myelofibrosis.
Cailin ConnerMyelofibrosis | October 8, 2024
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Cailin ConnerMyelofibrosis | October 8, 2024
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
Cailin ConnerMyelofibrosis | October 8, 2024
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
Cailin ConnerMyelofibrosis | October 9, 2024
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Andrew MorenoMyelofibrosis | September 30, 2024
A real-world retrospective study evaluated transfusion dependent or nondependent patients at ruxolitinib initiation.
Andrew MorenoMyelofibrosis | September 27, 2024
Management of asymptomatic, clinically stable disease is not necessarily improved by implementing routine hemostasis tests.
Andrew MorenoMyelofibrosis | September 27, 2024
Investigational agent DISC-0974 produced anemia response independent of patient transfusion dependency or JAK inhibitor use.
Andrew MorenoMyelofibrosis | September 26, 2024
A study observed that addition of pelabresib to ruxolitinib led to bone marrow microenvironment improvement.
Prithviraj Bose, MDMyelofibrosis | September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Melissa BadamoMyelofibrosis | September 13, 2024
History of thrombotic events, hematocrit ≤0.45 L/L, and JAK2 p.V617F were identified as risk factors for progression.
Melissa BadamoMyelofibrosis | September 13, 2024
LOXL2 upregulation is associated with key inflammatory signaling pathways in primary myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
Treatment with selinexor reduced hepcidin and pro-inflammatory cytokines in patients with myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
The rates of baseline comorbidities and constitutional symptoms were higher in patients with anemia versus those without.
Rob DillardMyelofibrosis | September 10, 2024
New or worsening anemia following initiation of ruxolitinib does not appear to diminish clinical benefit.
Rob DillardMyelofibrosis | September 10, 2024
Hemoglobin improvement at week 24 after transfusion is associated with improved HRQOL in myelofibrosis and anemia.
Rob DillardMyelofibrosis | September 10, 2024
Prospective analysis suggest that 4.3% of patients with ET progressed to myelofibrosis over five years of follow up.
Rob DillardMyelofibrosis | September 10, 2024
Patients with MF or ET with CALR or JAK2 mutations carried similar symptom burdens according to prospective data.
Julie GouldMyelofibrosis | September 9, 2024
The phase III MANIFEST-2 trial compared pelabresib plus ruxolitinib with placebo plus ruxolitinib in JAKi-naive patients.
Julie GouldMyelofibrosis | September 6, 2024
The findings were from a retrospective study of patient data from the US Flatiron Health electronic health record database.
Julie GouldMyelofibrosis | September 9, 2024
A retrospective analysis covered two phase III trials of the JAK2 inhibitor in patients with and without monocytosis.
Advertisement
Section Editor

Advertisement